On May 30 a paper by Luc Bousset and Ronald Melki on two new polymorphic structures of alpha-synuclein solved by cryo-electron microscopy was published in bioRxiv. Access to the article.
On May 21 The Plain English information about the research being conducted on Parkinson's, "The Science Of parkinson" posted on its twitter account about a review from the IMPRiND UMG-GOE team saying: "Interesting review of how #Parkinsons-associated α-Synuclein & #Alzheimers-associated Tau might be spreading. A systematic comparison of the various mechanisms involved" The Twitter post here!
To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes information on possible future topics well in advance of the official Call launch.
Future Call dates
IMI’s next Calls for proposals are currently planned for 26/06/2019. This date is indicative and may change.
IMI2 - Calls 18 & 19
The following topics are under consideration for inclusion in the next IMI Calls for proposals (IMI2 - Calls 18 and 19, which will be launched at the same time). These topics are now at an advanced stage of development and we hope that these drafts will allow potential applicants to start working actively on proposals and forming consortia. Draft topic texts are subject to consultations involving IMI's States Representatives Group, Scientific Committee, and the European Commission. They must also be approved by the IMI Governing Board. Depending on the results of the consultations and approval process, the final topic text may differ significantly from the draft versions initially published here, and applicants should always base their proposals on the final, approved topic texts which will be published when the Call is officially launched. Furthermore, although it is unlikely at this stage, it is possible that a draft topic may be postponed to a future Call or dropped entirely.
Today, 11 April 2019 is the World Parkinson's day, a campaign to increase understanding of Parkinson’s as a serious condition. We kindly invite you to join the activities world-wide eg via the Parkinson foundation!
Learn more about IMPRiND's approach to neurodegenerative diseases such as Parkinson's on our website!
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.